Clinical Interventions on Drug Interactions Frequently Required During Treatment
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers from the Netherlands have found that clinical interventions on drug-drug interactions are frequently required among ambulatory patients with cancer starting anticancer treatment.
Drug-drug interactions are a major concern in oncology because patients may take many concomitant medications.
Therefore, researchers sought to investigate the total number of clinical interventions on drug-drug interactions among a sample of ambulatory patients with cancer starting anticancer treatment.
The researchers enrolled 302 patients. Drug interaction software identified 603 drug-drug interactions among these patients, and an expert team of clinical pharmacologists determined that 120 of those among 81 patients were potentially clinically relevant.
Of those, 13% already had a clinical intervention executed by the hemato(oncologist), but the clinical pharmacologists proposed an additional intervention in 14% of patients. The researchers identified the number of over-the-counter medications and the number of comorbidities as determinants.
The findings suggest that structured screening by (hemato)oncologists and clinical pharmacologists/pharmacists for potentially clinically relevant drug-drug interventions should occur prior to and during anticancer treatment.
Clinical interventions on drug-drug interactions are frequently required among ambulatory patients with cancer starting anticancer treatment.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Plastics and Cancer
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer